NL0015000DX5 - Common Stock
ATAI LIFE SCIENCES NV
NASDAQ:ATAI (4/18/2024, 7:00:00 PM)
After market: 1.9238 +0.01 (+0.72%)1.91
-0.07 (-3.54%)
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Berlin, Berlin and currently employs 119 full-time employees. The company went IPO on 2021-06-18. The firm engages in developing various treatments that focuses on various mental health disorders. The firm's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
ATAI LIFE SCIENCES NV
Wallstrasse 16
Berlin BERLIN 100022
P: 498921539035
CEO: Florian Brand
Employees: 119
Website: https://atai.life/
ATAI stock results show that ATAI Life Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment...
- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 -...
Here you can normally see the latest stock twits on ATAI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: